Latigo Biotherapeutics Inc. (NASDAQ: LTGO) Stock Competitors & Peer Comparison

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 1.1B. In comparison, RPRX has a market cap of 25.7B. Regarding current trading prices, LTGO is priced at $18.56 on the NASDAQ, while RPRX trades at $57.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of N/A, whereas RPRX's P/E ratio is 11.04. In terms of profitability, LTGO's ROE is N/A, compared to RPRX's ROE of +0.12%. Regarding short-term risk, LTGO is more volatile compared to RPRX. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check RPRX's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 1.1B. In comparison, CORT has a market cap of 12.3B. Regarding current trading prices, LTGO is priced at $18.56 on the NASDAQ, while CORT trades at $114.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of N/A, whereas CORT's P/E ratio is 326.37. In terms of profitability, LTGO's ROE is N/A, compared to CORT's ROE of +0.08%. Regarding short-term risk, LTGO is more volatile compared to CORT. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check CORT's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 1.1B. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, LTGO is priced at $18.56 on the NASDAQ, while WBA trades at $11.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of N/A, whereas WBA's P/E ratio is -1.64. In terms of profitability, LTGO's ROE is N/A, compared to WBA's ROE of -0.42%. Regarding short-term risk, LTGO is more volatile compared to WBA. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check WBA's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 1.1B. In comparison, LQDA has a market cap of 8.1B. Regarding current trading prices, LTGO is priced at $18.56 on the NASDAQ, while LQDA trades at $91.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of N/A, whereas LQDA's P/E ratio is 650.21. In terms of profitability, LTGO's ROE is N/A, compared to LQDA's ROE of +0.47%. Regarding short-term risk, LTGO is more volatile compared to LQDA. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check LQDA's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 1.1B. In comparison, KNSA has a market cap of 5.8B. Regarding current trading prices, LTGO is priced at $18.56 on the NASDAQ, while KNSA trades at $76.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of N/A, whereas KNSA's P/E ratio is 85.03. In terms of profitability, LTGO's ROE is N/A, compared to KNSA's ROE of +0.14%. Regarding short-term risk, LTGO is more volatile compared to KNSA. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check KNSA's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 1.1B. In comparison, TRLV has a market cap of 1.5B. Regarding current trading prices, LTGO is priced at $18.56 on the NASDAQ, while TRLV trades at $9.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of N/A, whereas TRLV's P/E ratio is -21.50. In terms of profitability, LTGO's ROE is N/A, compared to TRLV's ROE of -0.44%. Regarding short-term risk, LTGO is more volatile compared to TRLV. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check TRLV's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 1.1B. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, LTGO is priced at $18.56 on the NASDAQ, while HROWL trades at $25.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of N/A, whereas HROWL's P/E ratio is N/A. In terms of profitability, LTGO's ROE is N/A, compared to HROWL's ROE of -0.34%. Regarding short-term risk, LTGO is more volatile compared to HROWL. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check HROWL's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 1.1B. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, LTGO is priced at $18.56 on the NASDAQ, while HROWM trades at $26.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of N/A, whereas HROWM's P/E ratio is N/A. In terms of profitability, LTGO's ROE is N/A, compared to HROWM's ROE of -0.34%. Regarding short-term risk, LTGO is more volatile compared to HROWM. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check HROWM's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 1.1B. In comparison, CUVL has a market cap of 339.9M. Regarding current trading prices, LTGO is priced at $18.56 on the NASDAQ, while CUVL trades at $6.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of N/A, whereas CUVL's P/E ratio is N/A. In terms of profitability, LTGO's ROE is N/A, compared to CUVL's ROE of N/A. Regarding short-term risk, LTGO is more volatile compared to CUVL. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check CUVL's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 1.1B. In comparison, LFMD has a market cap of 175.1M. Regarding current trading prices, LTGO is priced at $18.56 on the NASDAQ, while LFMD trades at $3.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of N/A, whereas LFMD's P/E ratio is -7.24. In terms of profitability, LTGO's ROE is N/A, compared to LFMD's ROE of -1.79%. Regarding short-term risk, LTGO is more volatile compared to LFMD. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check LFMD's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 1.1B. In comparison, LFMDP has a market cap of 160.2M. Regarding current trading prices, LTGO is priced at $18.56 on the NASDAQ, while LFMDP trades at $23.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of N/A, whereas LFMDP's P/E ratio is -724.19. In terms of profitability, LTGO's ROE is N/A, compared to LFMDP's ROE of -1.79%. Regarding short-term risk, LTGO is more volatile compared to LFMDP. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check LFMDP's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 1.1B. In comparison, CIRC has a market cap of 63M. Regarding current trading prices, LTGO is priced at $18.56 on the NASDAQ, while CIRC trades at $0.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of N/A, whereas CIRC's P/E ratio is -1.59. In terms of profitability, LTGO's ROE is N/A, compared to CIRC's ROE of +0.00%. Regarding short-term risk, LTGO is more volatile compared to CIRC. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check CIRC's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 1.1B. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, LTGO is priced at $18.56 on the NASDAQ, while RAD trades at $0.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of N/A, whereas RAD's P/E ratio is -0.05. In terms of profitability, LTGO's ROE is N/A, compared to RAD's ROE of +2.76%. Regarding short-term risk, LTGO is less volatile compared to RAD. This indicates lower risk in terms of short-term price fluctuations for LTGO.Check RAD's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 1.1B. In comparison, GLTO has a market cap of 34.5M. Regarding current trading prices, LTGO is priced at $18.56 on the NASDAQ, while GLTO trades at $21.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of N/A, whereas GLTO's P/E ratio is -1.78. In terms of profitability, LTGO's ROE is N/A, compared to GLTO's ROE of -1.22%. Regarding short-term risk, LTGO is more volatile compared to GLTO. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check GLTO's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 1.1B. In comparison, SCYX has a market cap of 32.4M. Regarding current trading prices, LTGO is priced at $18.56 on the NASDAQ, while SCYX trades at $5.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of N/A, whereas SCYX's P/E ratio is -1.51. In terms of profitability, LTGO's ROE is N/A, compared to SCYX's ROE of -0.57%. Regarding short-term risk, LTGO is more volatile compared to SCYX. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check SCYX's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 1.1B. In comparison, NSRX has a market cap of 29.4M. Regarding current trading prices, LTGO is priced at $18.56 on the NASDAQ, while NSRX trades at $3.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of N/A, whereas NSRX's P/E ratio is -4.74. In terms of profitability, LTGO's ROE is N/A, compared to NSRX's ROE of +0.00%. Regarding short-term risk, LTGO is more volatile compared to NSRX. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check NSRX's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 1.1B. In comparison, SDEV has a market cap of 27.6M. Regarding current trading prices, LTGO is priced at $18.56 on the NASDAQ, while SDEV trades at $1.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of N/A, whereas SDEV's P/E ratio is -0.18. In terms of profitability, LTGO's ROE is N/A, compared to SDEV's ROE of +7.90%. Regarding short-term risk, LTGO is more volatile compared to SDEV. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check SDEV's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 1.1B. In comparison, CNSY has a market cap of 26.4M. Regarding current trading prices, LTGO is priced at $18.56 on the NASDAQ, while CNSY trades at $3.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of N/A, whereas CNSY's P/E ratio is -0.53. In terms of profitability, LTGO's ROE is N/A, compared to CNSY's ROE of N/A. Regarding short-term risk, LTGO is more volatile compared to CNSY. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check CNSY's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 1.1B. In comparison, BFRI has a market cap of 15.5M. Regarding current trading prices, LTGO is priced at $18.56 on the NASDAQ, while BFRI trades at $1.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of N/A, whereas BFRI's P/E ratio is -1.13. In terms of profitability, LTGO's ROE is N/A, compared to BFRI's ROE of -4.77%. Regarding short-term risk, LTGO is more volatile compared to BFRI. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check BFRI's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 1.1B. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, LTGO is priced at $18.56 on the NASDAQ, while CJJD trades at $1.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of N/A, whereas CJJD's P/E ratio is -0.46. In terms of profitability, LTGO's ROE is N/A, compared to CJJD's ROE of -0.25%. Regarding short-term risk, LTGO is more volatile compared to CJJD. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check CJJD's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 1.1B. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, LTGO is priced at $18.56 on the NASDAQ, while SSY trades at $1.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of N/A, whereas SSY's P/E ratio is -2.86. In terms of profitability, LTGO's ROE is N/A, compared to SSY's ROE of -0.09%. Regarding short-term risk, LTGO is less volatile compared to SSY. This indicates lower risk in terms of short-term price fluctuations for LTGO.Check SSY's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 1.1B. In comparison, POM has a market cap of 7.3M. Regarding current trading prices, LTGO is priced at $18.56 on the NASDAQ, while POM trades at $1.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of N/A, whereas POM's P/E ratio is -0.21. In terms of profitability, LTGO's ROE is N/A, compared to POM's ROE of +0.16%. Regarding short-term risk, LTGO is less volatile compared to POM. This indicates lower risk in terms of short-term price fluctuations for LTGO.Check POM's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 1.1B. In comparison, PAVS has a market cap of 6.4M. Regarding current trading prices, LTGO is priced at $18.56 on the NASDAQ, while PAVS trades at $7.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of N/A, whereas PAVS's P/E ratio is -0.08. In terms of profitability, LTGO's ROE is N/A, compared to PAVS's ROE of -0.27%. Regarding short-term risk, LTGO is less volatile compared to PAVS. This indicates lower risk in terms of short-term price fluctuations for LTGO.Check PAVS's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 1.1B. In comparison, HKPD has a market cap of 4.6M. Regarding current trading prices, LTGO is priced at $18.56 on the NASDAQ, while HKPD trades at $0.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of N/A, whereas HKPD's P/E ratio is -6.99. In terms of profitability, LTGO's ROE is N/A, compared to HKPD's ROE of -0.14%. Regarding short-term risk, LTGO is less volatile compared to HKPD. This indicates lower risk in terms of short-term price fluctuations for LTGO.Check HKPD's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 1.1B. In comparison, AIXC has a market cap of 4.1M. Regarding current trading prices, LTGO is priced at $18.56 on the NASDAQ, while AIXC trades at $0.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of N/A, whereas AIXC's P/E ratio is -0.09. In terms of profitability, LTGO's ROE is N/A, compared to AIXC's ROE of -0.94%. Regarding short-term risk, LTGO is less volatile compared to AIXC. This indicates lower risk in terms of short-term price fluctuations for LTGO.Check AIXC's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 1.1B. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, LTGO is priced at $18.56 on the NASDAQ, while MDVL trades at $1.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of N/A, whereas MDVL's P/E ratio is -0.05. In terms of profitability, LTGO's ROE is N/A, compared to MDVL's ROE of -2.39%. Regarding short-term risk, LTGO is less volatile compared to MDVL. This indicates lower risk in terms of short-term price fluctuations for LTGO.Check MDVL's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 1.1B. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, LTGO is priced at $18.56 on the NASDAQ, while ATNFW trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of N/A, whereas ATNFW's P/E ratio is N/A. In terms of profitability, LTGO's ROE is N/A, compared to ATNFW's ROE of -2.41%. Regarding short-term risk, LTGO is less volatile compared to ATNFW. This indicates lower risk in terms of short-term price fluctuations for LTGO.Check ATNFW's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 1.1B. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, LTGO is priced at $18.56 on the NASDAQ, while BGMSP trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of N/A, whereas BGMSP's P/E ratio is -0.84. In terms of profitability, LTGO's ROE is N/A, compared to BGMSP's ROE of -0.51%. Regarding short-term risk, LTGO is more volatile compared to BGMSP. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check BGMSP's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 1.1B. In comparison, BGMS has a market cap of 2M. Regarding current trading prices, LTGO is priced at $18.56 on the NASDAQ, while BGMS trades at $0.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of N/A, whereas BGMS's P/E ratio is -0.25. In terms of profitability, LTGO's ROE is N/A, compared to BGMS's ROE of -0.51%. Regarding short-term risk, LTGO is more volatile compared to BGMS. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check BGMS's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 1.1B. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, LTGO is priced at $18.56 on the NASDAQ, while AZNH trades at $53.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of N/A, whereas AZNH's P/E ratio is 38.35. In terms of profitability, LTGO's ROE is N/A, compared to AZNH's ROE of +0.00%. Regarding short-term risk, LTGO is more volatile compared to AZNH. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check AZNH's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 1.1B. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, LTGO is priced at $18.56 on the NASDAQ, while LFLYW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of N/A, whereas LFLYW's P/E ratio is -0.00. In terms of profitability, LTGO's ROE is N/A, compared to LFLYW's ROE of +0.42%. Regarding short-term risk, LTGO is more volatile compared to LFLYW. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check LFLYW's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 1.1B. In comparison, SBFMW has a market cap of 175.2K. Regarding current trading prices, LTGO is priced at $18.56 on the NASDAQ, while SBFMW trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of N/A, whereas SBFMW's P/E ratio is N/A. In terms of profitability, LTGO's ROE is N/A, compared to SBFMW's ROE of -0.26%. Regarding short-term risk, LTGO is less volatile compared to SBFMW. This indicates lower risk in terms of short-term price fluctuations for LTGO.Check SBFMW's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 1.1B. In comparison, ESRX has a market cap of 0. Regarding current trading prices, LTGO is priced at $18.56 on the NASDAQ, while ESRX trades at $92.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of N/A, whereas ESRX's P/E ratio is 10.69. In terms of profitability, LTGO's ROE is N/A, compared to ESRX's ROE of +0.26%. Regarding short-term risk, LTGO is more volatile compared to ESRX. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check ESRX's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 1.1B. In comparison, POZN has a market cap of 0. Regarding current trading prices, LTGO is priced at $18.56 on the NASDAQ, while POZN trades at $5.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of N/A, whereas POZN's P/E ratio is N/A. In terms of profitability, LTGO's ROE is N/A, compared to POZN's ROE of +0.61%. Regarding short-term risk, LTGO is less volatile compared to POZN. This indicates lower risk in terms of short-term price fluctuations for LTGO.Check POZN's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 1.1B. In comparison, OREX has a market cap of 0. Regarding current trading prices, LTGO is priced at $18.56 on the NASDAQ, while OREX trades at $0.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of N/A, whereas OREX's P/E ratio is -0.14. In terms of profitability, LTGO's ROE is N/A, compared to OREX's ROE of -0.54%. Regarding short-term risk, LTGO is less volatile compared to OREX. This indicates lower risk in terms of short-term price fluctuations for LTGO.Check OREX's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 1.1B. In comparison, IPXL has a market cap of 0. Regarding current trading prices, LTGO is priced at $18.56 on the NASDAQ, while IPXL trades at $18.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of N/A, whereas IPXL's P/E ratio is -10.11. In terms of profitability, LTGO's ROE is N/A, compared to IPXL's ROE of -1.16%. Regarding short-term risk, LTGO is more volatile compared to IPXL. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check IPXL's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 1.1B. In comparison, CPD has a market cap of 0. Regarding current trading prices, LTGO is priced at $18.56 on the NASDAQ, while CPD trades at $5.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of N/A, whereas CPD's P/E ratio is N/A. In terms of profitability, LTGO's ROE is N/A, compared to CPD's ROE of N/A. Regarding short-term risk, LTGO is more volatile compared to CPD. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check CPD's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 1.1B. In comparison, SHPG has a market cap of 0. Regarding current trading prices, LTGO is priced at $18.56 on the NASDAQ, while SHPG trades at $179.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of N/A, whereas SHPG's P/E ratio is 11.35. In terms of profitability, LTGO's ROE is N/A, compared to SHPG's ROE of +0.13%. Regarding short-term risk, LTGO is more volatile compared to SHPG. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check SHPG's competition here